Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells.
Matteo GiuliettiFrancesco PivaMonia CecatiSerena MaggioMichele GuesciniTiziana SaladinoLaura ScortichiniSonia CrocettiMiriam CaramantiNicola BattelliEmanuela RomagnoliPublished in: Cells (2024)
Extracellular vesicles (EVs) are small lipid particles secreted by almost all human cells into the extracellular space. They perform the essential function of cell-to-cell communication, and their role in promoting breast cancer progression has been well demonstrated. It is known that EVs released by triple-negative and highly aggressive MDA-MB-231 breast cancer cells treated with paclitaxel, a microtubule-targeting agent (MTA), promoted chemoresistance in EV-recipient cells. Here, we studied the RNA content of EVs produced by the same MDA-MB-231 breast cancer cells treated with another MTA, eribulin mesylate. In particular, we analyzed the expression of different RNA species, including mRNAs, lncRNAs, miRNAs, snoRNAs, piRNAs and tRNA fragments by RNA-seq. Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.
Keyphrases
- breast cancer cells
- single cell
- network analysis
- rna seq
- induced apoptosis
- cell cycle arrest
- poor prognosis
- metastatic breast cancer
- squamous cell carcinoma
- genome wide identification
- cell therapy
- cell death
- magnetic resonance
- phase ii
- newly diagnosed
- randomized controlled trial
- nucleic acid
- signaling pathway
- stem cells
- gene expression
- cancer therapy
- pi k akt
- transcription factor
- fatty acid
- long non coding rna
- drug delivery
- dna methylation
- young adults